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Background
Surgical resection of metastatic cancer is beneficial in
select patients with cancer. HD IL-2 is an FDA
approved immunotherapy for the treatment of patients
with melanoma or renal cell carcinoma. IL-2 induces a
complete response (CR) in 4-10% of patients while an
additional 10% of patients have a partial response (PR).
While not frequently reported, our experience suggests
an additional 20% of patients have a stable response
(SD) to therapy. The subsequent management of
patients with an incomplete response, either partial or
stable, has not been well studied and we sought to
determine if metastasectomy might have a role in this
setting.
Methods
305 patients with metastatic renal cell carcinoma or
melanoma treated with IL-2 therapy over a 12-year per-
iod were reviewed. Age, response and survival data were
available for 215 patients. Response was determined
using standard RECIST criteria and patients with partial
response (PR) or stable disease (SD) were considered
incomplete responders to IL-2. Patients with an incom-
plete response were evaluated by a surgical oncologist.
Surgical complete response (sCR) was defined as com-
plete surgical resection of a single or multiple sites of
disease following IL-2 therapy that rendered patients
free of disease. Overall survival was estimated analyzed
using Kaplan-Meier curves and compared between
groups using the log-rank test.
Results
The objective response rate (PR + CR) to HD IL-2 in
this cohort was 13.6%. An additional 24.4% of patients
had SD following their initial course of therapy. Median
survival of all treated patients was 16.8 months. Incom-
plete response to IL-2 does confer an improvement in
overall survival compared to patients with progressive
disease (median survival 38.2 v. 7.9 months). Eighty-one
patients had an incomplete response (PR + SD) to IL-2,
fifteen of whom underwent subsequent metastasectomy.
Patients undergoing metastasectomy had improved over-
all survival compared to patients with an incomplete
response that did not undergo subsequent surgery (38.2
months v. median not reached in surgical patients,
p=0.026). Of patients treated surgically following HD
IL-2 12 patients were alive at the end of follow-up with
follow-up ranging from 15 months to 96 months.
Conclusion
The addition of surgical resection may improve upon
the survival benefit in select patients with incomplete
response to HD IL-2. These findings are biased by
patient selection, but our results support the rationale
for a prospective trial to determine the role of metasta-
sectomy following incomplete response to IL-2 therapy.
Additionally, we are interested in understanding how
surgical resection following immunotherapy may reset
immunologic balance in patients with metastatic cancer.
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